Exercise for Depression

Bipolar Disorder Clinical Trial

— EXDEP  

Official title:

The Efficacy of Exercise in Depressive Episodes of Unipolar Depression and Bipolar Affective Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02874833
• Other study ID #: EXDEP_1
• Status: Completed
• Phase: N/A
• First received: August 8, 2016
• Last updated: February 28, 2018
• Start date: July 2016
• Est. completion date: February 2018

Study information

• Verified date: February 2018
• Source: Johannes Gutenberg University Mainz
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized single-blinded prospective study to evaluate the efficacy of an individualized supervised 8-week exercise program in subjects with moderate to severe depressive episodes compared to treatment-as-usual

Description:

The purpose of this study is to assess the efficacy of a supervised and indvidualized 8-week exercise program compared to treatment-as-usual in subjects with a moderate or severe depressive episode in the context of unipolar depression or bipolar affective disorders. Numerous previous studies suggest that exercise may help to improve the symptoms of depression. Moreover, exercise was shown to enhance neuroplasticity in adults whereas depression results in decreased neuroplasticity. Here, we aim at elucidating whether a newly developed supervised, Internet-based, individualized exercise program of the Institute of Sports Science and the Department of Psychiatry and Psychotherapy at the University Mainz is more effective in reducing depressive symptoms than treatment-as-usual. Furthermore, this study will clarify if severely depressed subjects are able to adhere to an internet-based exercise therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 2018
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations.

2. Aged 18 to 65 years old, inclusive, at the time of informed consent.

3. Montral Cognitive Assessment (MoCA) > 26 to exclude cognitive impairment.

4. Apart from a clinical diagnosis of major depression or bipolar affective disorder, the subject must be in good health as determined by the Investigator, based on medical history and physical examination.

5. QIDS scores > 5

Exclusion Criteria:

1. Use of antidepressive medications or benzodiazepines at doses that have not been stable for at least 6 weeks prior to Screening

2. Psychotherapy that started less than 8 weeks prior to Screening

3. Any clinically significant psychiatric illness other than major depression or bipolar affective disorder

4. Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening

5. Any uncontrolled medical or neurological/neurodegenerative condition that, in the opinion of the Investigator, might impair treatment compliance and adherence

6. History of unstable angina, myocardial infarction, chronic heart failure (New York Heart Association Class III or IV), or clinically significant conduction abnormalities (e.g., unstable atrial fibrillation) within 1 year prior to Screening

7. Clinically significant 12-lead ECG abnormalities, as determined by the Investigator

8. Uncontrolled hypertension defined as: average of 3 systolic blood pressure [SBP]/diastolic blood pressure [DBP] readings > 165/100 mmHg at Screening

9. History of malignancy or carcinoma, with the following exceptions:

i) Subjects with cancers in remission more than 5 years prior to Screening. ii) Subjects with a history of excised or treated basal cell or squamous carcinoma. iii) Subjects with prostate cancer in situ.

10. History of seizure within 2 years prior to Screening.

11. Recent history (within 1 year of Screening) of alcohol or substance abuse as determined by the Investigator, a positive urine drug (due to non-prescription drug) or alcohol test at Screening

12. Clinically significant systemic illness or serious infection (e.g., pneumonia, septicemia) within 30 days prior to or during Screening

13. History of human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)

14. Any other medical conditions (e.g., renal disease) that are not stable or controlled, or, which in the opinion of the Investigator, could affect the subject's safety or interfere with the study assessments

15. Female subjects who are pregnant or currently breastfeeding

16. Participation in another study

17. Other unspecified reasons that, in the opinion of the Investigator or Biogen, make the subject unsuitable for enrollment

Related Conditions & MeSH terms

• Bipolar Disorder
• Depression
• Depression, Unipolar
• Depressive Disorder
• Mood Disorders

Intervention

Other:
• Exercise
After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.

Locations

Country	Name	City	State
Germany	Department of Psychiatry and Psychotherapy, University Medical Center, Mainz	Mainz	Rhineland-Palatinate
Germany	Department of Sports Medicine, Johannes Gutenberg University, Mainz	Mainz	Rhineland-Palatinate

Sponsors (2)

Lead Sponsor	Collaborator
Johannes Gutenberg University Mainz	Department of Psychiatry and Psychotherapy, University Medical Center, Mainz

Country where clinical trial is conducted

Germany, 

References & Publications (4)

Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, McMurdo M, Mead GE. Exercise for depression. Cochrane Database Syst Rev. 2013 Sep 12;(9):CD004366. doi: 10.1002/14651858.CD004366.pub6. Review. — View Citation

Malykhin NV, Coupland NJ. Hippocampal neuroplasticity in major depressive disorder. Neuroscience. 2015 Nov 19;309:200-13. doi: 10.1016/j.neuroscience.2015.04.047. Epub 2015 Apr 28. Review. — View Citation

van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci. 2005 Sep 21;25(38):8680-5. — View Citation

Yau GS, Lee JW, Woo TT, Wong RL, Wong IY. Central Macular Thickness in Children with Myopia, Emmetropia, and Hyperopia: An Optical Coherence Tomography Study. Biomed Res Int. 2015;2015:847694. doi: 10.1155/2015/847694. Epub 2015 Jun 8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severity of depressive symptoms - Quick Inventory of Depressive Symptomatology - clinical rating-16 (QIDS C-16)	Change of Score on the QIDS C-16 after 8 weeks compared to baseline.	8 weeks
Primary	Severity of depressive symptoms - Quick Inventory of Depressive Symptomatology - self-report-16 (QIDS SR-16)	Change of Score on the QIDS SR-16 after 8 weeks compared to baseline.	8 weeks
Secondary	Adherence of internet-based concept	Adherence of internet-based concept using an own questionnaire. Participants respond at the end of every week how they managed their individualized exercise schedule in terms of number of realised training sessions, average heart rate and subjective perceived exertion.	8 weeks
Secondary	Placebo effect of exercise (QIDS-SR16)	Change of Score on the QIDS-SR16 after one week of training to determine placebo effect of exercise.	8-10 days
Secondary	Placebo effect of exercise (QIDS-C16)	Change of Score on the QIDS-C16 after one week of training to determine placebo effect of exercise.	8-10 days
Secondary	Peak oxygen uptake (VO2peak)	Change of VO2peak after 8 weeks compared to baseline. Participants will be subjected to a step-wise treadmill test at baseline and after 8 weeks.	8 weeks
Secondary	Lactate threshold	Change of lactate threshold using the baseline +1.5 mmol model after 8 weeks compared to baseline.	8 weeks
Secondary	Short form 36 (SF36) health survey questionnaire	Change of score on the SF-36 after 8 weeks compared to baseline.	8 weeks
Secondary	General self efficacy questionnaire (GSE)	Change of score on the GSE after 8 weeks compared to baseline.	8 weeks
Secondary	Global Clinical Issues (GCI)	Change of score on GCI after 8 weeks compared to baseline.	8 weeks
Secondary	Circulating, cell-free DNA (cfDNA)	Change of cfDNA concentrations after 8 weeks compared to baseline.	8 weeks